GlassScriptPhysician profile
Morgan L Stamper
NPI 1336752104
$42,080.83
in general payments reported to CMS, 2019-2025
25 companies · $6,049 in 2025
The $6,049 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,324 · 2022: $7,769 · 2023: $18K · 2024: $8,485 · 2025: $6,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $2,749 · Travel and Lodging: $1,325 · Consulting Fee: $230 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,625.00 |
| Food and Beverage | $2,749.37 |
| Travel and Lodging | $1,324.71 |
| Consulting Fee | $230.00 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,795.63 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $840.11 | 2021-2025 | Caplyta |
| Uswm, LLC | $578.93 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $472.43 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $286.65 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $262.94 | 2021-2025 | Fanapt |
| Janssen Scientific Affairs, LLC | $230.00 | 2024-2025 | Spravato |
| Indivior INC. | $212.69 | 2021-2025 | Sublocade, Perseris |
| Lundbeck LLC | $188.65 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $186.98 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $171.18 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $165.25 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $124.70 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $110.59 | 2021-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $106.14 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $92.45 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $68.88 | 2021 | |
| Axsome Therapeutics, INC. | $52.21 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $37.90 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $28.27 | 2025 | Cobenfy |
| Tris Pharma INC | $15.97 | 2024 | Dyanavel Xr |
| Orexo US, INC. | $14.33 | 2022 | |
| Braeburn INC. | $13.64 | 2025 | Brixadi |
| Allergan, INC. | $12.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Stamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.